Baker Keith
Direttore/Membro del Consiglio presso Gyroscope Therapeutics Ltd.
Profilo
Keith Baker, MD, MBA is a graduate of Duke University, Dartmouth (Geisel) Medical School, and the Amos Tuck School of Business Administration at Dartmouth College.
Dr. Baker completed his Ophthalmology residency training at the University of North Carolina Hospitals in Chapel Hill, NC, where he was selected as Chief Resident during his final year of training.
He completed his board certification in Ophthalmology and was elected to membership in the American Academy of Ophthalmology.
Dr. Baker has participated in eye care medical mission trips to China, El Salvador, and rural Appalachia.
Since 2010, Dr. Baker has worked in the life sciences industry as a strategy consultant and Medical Affairs professional.
In that capacity, Keith has focused on identifying and addressing unmet clinical needs within the Ophthalmology space and has developed extensive experience in market assessment, clinical trial conception and execution, and communication of relevant data to a wide variety of stakeholders.
Dr. Baker has served as an informal adviser to Dr. David Adair on multiple occasions since 2011 and joined the Solas Advisory Board in February of 2021.
Posizioni attive di Baker Keith
Società | Posizione | Inizio |
---|---|---|
Solas Bioventures (mayfield) LLC
Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas Bioventures (mayfield) LLC is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | Consulente / Consigliere | - |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Direttore/Membro del Consiglio | 01/04/2021 |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Investitore di Private Equity | 01/01/2023 |
Formazione di Baker Keith
Tuck School of Business at Dartmouth | Masters Business Admin |
Geisel School of Medicine | Doctorate Degree |
Duke University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Solas Bioventures (mayfield) LLC
Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas Bioventures (mayfield) LLC is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | Finance |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Health Technology |
- Borsa valori
- Insiders
- Baker Keith